In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Prognostic importance of culprit lesion location in cardiogenic shock due to myocardial infarction

Session Moderated Poster 4: Cardiogenic shock

Speaker Jakob Josiassen

Event : Acute Cardiovascular Care 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Cardiac Care – Cardiogenic Shock
  • Session type : Moderated Posters

Authors : J Josiassen (Copenhagen,DK), OK Moeller-Helgestad (Odense,DK), JE Moeller (Odense,DK), L Holmvang (Copenhagen,DK), LO Jensen (Odense,DK), NJ Udesen (Odense,DK), HB Ravn (Copenhagen,DK), C Hassager (Copenhagen,DK)

J Josiassen1 , OK Moeller-Helgestad2 , JE Moeller2 , L Holmvang1 , LO Jensen2 , NJ Udesen2 , HB Ravn3 , C Hassager1 , 1Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre - Copenhagen - Denmark , 2Odense University Hospital, Department of Cardiology - Odense - Denmark , 3Rigshospitalet - Copenhagen University Hospital, Department of Cardiothoracic anaesthesiology, The Heart Centre - Copenhagen - Denmark ,


Cardiogenic shock (CS) after myocardial infarction (MI) carries 30-day mortality rates as high as 50%. Location of culprit lesion can be in all coronary arteries, but most frequently in the left anterior descending (LAD) artery. Whether location of culprit lesion is of prognostic importance in patients with CS following MI remains unknown in contemporary data.

The aim of the study was to describe mortality in CS patients in relation to culprit lesion was location.

From the recruitment area of two tertiary heart centres in Denmark, covering 3.9 million citizens corresponding to two-thirds of the Danish population, all patients admitted with CS due to MI in the period of 2010-2017 were identified through patient records.

A total of 1716 patients with CS were identified. Acute revascularisation was performed in 1482 patients (86%). Among these 44% had the culprit lesion in the LAD, 29% in the right coronary artery (RCA), 14% in the left circumflex (LCX) and 13% in the left main (LM). Patients who were not revascularized had the highest 30-day mortality (86%), followed by patients with a culprit lesion in the LM (66 %), while a culprit lesion in the remaining coronary arteries had comparable and significantly lower mortality (43-48%), p<0.0001 (Figure1). These differences remained significant after multivariate adjustment for age, gender and lactate, heart rate, comatose (yes/no) in CS patients (RCA vs LAD: Hazard ratio (HR) 1.11; 95% confidence interval (CI) 0.90-1.36; p=0.34, LCX vs LAD: HR 0.88; CI 0.66-1.17; p=0.37, LM vs LAD: HR 1.70; CI1.33-2.17; p=<0.0001, Not Revascularized vs LAD: HR 2.96; CI 2.39-3.68; p=<0.0001). Comment: The prognostic importance of single- vs multivessel disease will also be presented.

CS due to culprit lesion in the LAD, RCA and LCX had comparable 30-day mortality rates, whereas patients with culprit in LM had a significantly higher mortality rate. Patients who did not get revascularized carried the gravest prognosis.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are